Liver X receptor-alpha (LXR-a), being a member of the nuclear receptor/transcription factor family, has been widely recognized to have a pleiotropic effect in the regulation of genes involved in innate immunity, inflammation and cholesterol homeostasis. Keeping in view the fact that psoriasis is a chronic, inflammatory and autoimmune disease with a high turnover of keratinocytes, this study was addressed to understand the functional RNomics of the LXR-a gene in cultured primary keratinocytes derived from skin biopsies of human psoriatic lesions, and from symptomless skin of psoriatic patients and clinically healthy subjects. The results of this study revealed for the first time that the LXR-a gene has an inherent capacity to regulate genes coding for inflammatory cytokines, cell cycle, immunomodulation and reactive oxygen species scavenging within human keratinocytes. Moreover, LXR-a gene knockdown within normal human keratinocytes simulated the genomic profile observed in psoriatic skin lesions. On the basis of our study, we propose that restoration of LXR-a expression/function within a psoriatic lesion may help to switch the transition from psoriatic to symptomless skin.
Introduction
There exists a general recognition of the fact that psoriasis can be defined as a chronic, inflammatory and autoimmune skin disorder characterized by an accelerated rate of keratinocyte proliferation, coupled with the production of inflammatory cytokines. 1 Liver X receptoralpha (LXR-a) belongs to the nuclear receptor/transcription factor superfamily and has been implicated in the stimulation of epidermal differentiation and development. 2, 3 Furthermore, LXR-a has been unambiguously shown to regulate genes involved in lipid peroxidation and inflammation. 4 Keeping in view the fact that the role of LXR-a has not been explored in psoriasis so far, our investigation was directed toward understanding three specific issues: (a) Whether or not primary keratinocytes, cultured from skin biopsies of human subjects at their psoriatic lesion site, as well as at the symptomless skin site, coupled with skin biopsies from clinically healthy subjects, have the inherent capacity to express the LXR-a gene; (b) If yes, how selective and specific LXR-a gene knockdown within cultured primary keratinocytes obtained from skin biopsies of clinically healthy subjects could influence the genes involved in inflammation as well as in keratinocyte proliferation; (c) Does LXR-a gene knockdown in these cultured primary keratinocytes depict a genomic expression profile identical to that observed in cultured primary keratinocytes from psoriatic lesions of patients.
Results
Immunochemical localization of cytokeratin within primary cultures obtained from skin biopsies revealed that these cultured cells were indeed keratinocytes ( Figure 1 ). Although keratinocytes derived from skin biopsies of healthy subjects, and from symptomless and lesional skin of psoriatic patients, exhibited an expression of the LXR-a gene, keratinocytes from psoriatic lesions expressed significantly low levels of the LXR-a gene compared with that observed in keratinocytes derived from either healthy skin or symptomless skin of psoriatic patients ( Figure 2 ). Further experiments directed toward understanding the effect of LXR-a gene knockdown (both at the transcriptional and translational level) within normal human keratinocytes on the genes involved in inflammation and proliferation revealed that genes coding for peroxisome proliferator-activated receptor-gamma (PPAR-g), catalase and vitamin D receptor (VDR) were significantly downregulated, whereas genes coding for interferon-gamma (IFN-g), c-myc, interleukin-6 (IL-6) and interleukin-8 (IL-8) were significantly upregulated as compared with that found in control cells (Figures 3 and 4) . Furthermore, an attempt was made to explore whether LXR-a gene knockdown keratinocytes (derived from skin biopsies of clinically healthy subjects) exhibit a similar genomic profile as that in keratinocytes derived from lesional skin of psoriatic patients. The results of this study reported in Figure 5 revealed an identical pattern, indicating thereby that LXR-a may be of crucial importance in modulating the expression of these genes involved in the formation of psoriatic lesions. The exposure of LXR-a gene knockdown keratinocytes to 22-R hydroxycholestrol (natural agonist of LXR-a protein) did not significantly change the expression profile of LXR-a effector genes ( Figure 6 ) as compared with that observed in keratinocytes transfected with small interfering RNA (siRNA) specific to the LXR-a gene ( Figure 3 ). This view was further confirmed by our cell cycle analysis results ( Figure 7 ) that unambiguously showed that knockdown of the LXR-a gene within normal keratinocytes results in their increased transition to the S phase of the cell cycle. Moreover, a study directed at exploring catalase activity in keratinocytes derived from lesional and symptomless skin of psoriatic patients revealed a significant decrease in catalase activity within keratinocytes derived from lesional skin compared with that in symptomless skin ( Figure 8 ).
Discussion
Psoriasis has been recognized as a chronic inflammatory disease of the skin characterized by an accelerated rate of keratinocyte proliferation, alteration in dermal angiogenesis and increased production of proinflammatory cytokines. 5, 6 The nuclear receptor LXR-a has a welldocumented role in cholesterol homeostasis and inflammation. 7 Recently, the LXR-a gene has caught the imagination of dermatologists, 8, 9 keeping in view the fact that LXR-a has crucial role in keratinocyte proliferation and differentiation. [10] [11] [12] A new dimension was added to understanding the pathognomics of psoriasis by discovering that synthetic LXR-a-specific agonists had the inherent capacity to inhibit cell proliferation in primary epidermal keratinocytes. 13 It is in this context that the results reported here assume importance. Our study unambiguously shows that the LXR-a gene not only regulates the expression of proinflammatory cytokines but also that of VDR, PPAR-g, as well as that of catalase, an antioxidant enzyme responsible for scavenging reactive oxygen species (ROS) within primary epidermal keratinocytes, Figure 3 . A striking improvement in skin lesions had initially been documented in patients with psoriasis treated with the oral PPAR-g activator, troglitazone.
14 As ROS has been recognized to initiate inflammatory process in psoriasis, it is apparent that catalase neutralizes ROS and thereby inhibits the inflammatory process of psoriasis. 15 ROS also has an important role in the pathogenesis of inflammatory reactions, particularly in inflammatory skin diseases such as psoriasis, and the natural antioxidant catalase is known to regulate ROS, thereby exerting a crucial effect in this inflammatory disease. 16, 17 It is interesting to note at this stage that vitamin D3, through its specific receptor, has been shown to suppress psoriatic lesions topically. A potentially very important activity of VDR agonists is their capacity to inhibit T-helper 1 cell responses. These mechanisms of action can explain some of the immunoregulatory properties of VDR agonists in the treatment of T-helper 1-mediated autoimmune diseases. 18 It has also been found that an active form of vitamin D, 1,25-dihydroxyvitamin D(3), exhibits antiproliferative and immunoregulatory effects through the VDR, and thus is successfully used in the topical treatment of psoriasis. 19, 20 IL-8 is a chemotactic cytokine with proinflammatory and growth-promoting activities. Recently, it has been shown to influence several functions of keratinocytes, including chemotaxis and proliferation Role of LXR-a RNomics DS Gupta et al by binding to a specific receptor. 21 IL-6 is also of key importance as it stimulates the proliferation of both epidermal cells and lymphocytes, making it a candidate for orchestrating interactions between the epidermis and the immune system in inflammatory skin diseases. 22 Our study that shows the ability of the LXR-a gene to modulate genes ( Figure 3 ) coding for various cytokines and chemokines (for example, IL-6, IL-8 and IFN-g) attest Role of LXR-a RNomics DS Gupta et al the fact that the LXR-a gene may be of crucial importance in regulating the inflammatory process characteristic of psoriasis. Furthermore, the downregulatory effect of the LXR-a gene on c-myc gene expression (Figure 3) explains the mechanism by which LXR-a synthetic agonists inhibit the proliferation of keratinocytes in vivo. 13 The pathomechanism of psoriasis is a shift toward type 1 proinflammatory cytokines producing T cells occurring in the diseased condition. 23, 24 Hence, there is an overexpression of type 1 cytokines, such as IL-8 and IFN-g. It has also been observed that selective skewing of T-helper 1 cells toward an interleukin-4 (IL-4)-producing (T-helper 2) phenotype can, in experimental animals, alleviate autoimmune disease without inducing general immunosuppression. 25, 26 A decrease in the IFN-g expression and an increase in the IL-4 expression of T cells in psoriatic lesions after UVB irradiation lead to a decrease in local immunoreactivity. 27 The ability of LXR-a to modulate the expression of c-myc as in Figure 3 explains the mechanism by which LXR-a synthetic agonists inhibit the proliferation of keratinocytes in in vitro cultures. 28 Although CX3CR1 is expressed only in an inflammatory condition in the skin, 29 no expression of this gene was detected in either of the conditions in our study, whereas the expression of IL-6 was found in keratinocytes of healthy subjects and the expression of this gene was not observed in either the lesional or symptomless skin of psoriatic patients.
In addition, the results reported here clearly indicate that the observed LXR-a gene downregulation in primary keratinocytes from psoriatic skin displays identical genomic features to that observed in primary normal epidermal keratinocytes in which the LXR-a gene was specifically and selectively knocked down (Figures 3  and 5 ). Hence, our study for the first time shows that LXR-a may act as a molecular switch that initiates transition from symptomless skin to psoriatic skin.
Keeping in view the findings reported here, coupled with earlier reported findings, it is not unlikely that LXRa transcriptome may be of crucial importance not only in understanding the genomic basis of psoriasis but also in designing futuristic therapy for this skin disorder.
Materials and methods

Clinical samples
Patients with mild or moderate psoriasis (Psoriasis Area and Severity Index (PASI) X10), with no ongoing treatment for their psoriasis within 3 weeks, were selected from the outpatient clinic of the Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh. The age distribution of patients for this study was from 18 to 40 years. A 4-mm punch biopsy was performed on a clinically active lesional site and on symptomless skin from psoriatic patients (n ¼ 10) and healthy volunteers (n ¼ 6) with their written informed consent. This part of the study was approved by the Ethics Committee at the Postgraduate Institute of Medical Education.
Cellular model used
The biopsies were washed twice with phosphatebuffered saline (PBS) and kept in trypsin/EDTA solution Role of LXR-a RNomics DS Gupta et al (0.25/0.02%) overnight at 4 1C, followed by incubation at 37 1C for 30 min the next day. Fetal calf serum was added to inactivate the trypsin/EDTA. They were transferred to a Petri dish and then cells were detached with the help of a pair of forceps and gentle pipetting in PBS. The cells in PBS were centrifuged at 1000 g for 5 min and the supernatant was removed. Keratinocyte media (Gibco, Invitrogen Corporation, Carlsbad, CA, USA) were added to the pellet and mixed by gentle pipetting. The cells in the media were then seeded in 24-well culture plates.
Cultures were maintained at 37 1C in a humidified 5% CO 2 atmosphere with regular changes of medium every third day. The cells were grown to confluency till day 25 and subsequently used for all given experiments.
Immunochemical localization
Media were gently removed, followed by three washings with 1 Â PBS for 5 min each. Absolute methanol at room temperature for permeabilization was added, followed by three washings with 1 Â PBS. Blocking was carried out using 2.5% bovine serum albumin in PBS for 30-45 min, again followed by three washings with 1 Â PBS. Primary antibody Pan Cytokeratin (Sigma-Aldrich, St Louis, MO, USA) at a dilution of 1:20 was added and kept overnight at 4 1C. Next day, media were removed gently, followed again by three washings with 1 Â PBS for 5 min each. The cells were incubated with the secondary antibody. Finally, the cells were mounted with glycerol.
Bioinformatics analysis
Promoter sequences of various genes under investigation were obtained from the Mammalian Promoter Sequence Database, and the putative transcription factor binding sites for LXR-a on the promoters of the effector genes in the study were obtained using the JASPAR database (http://jaspar. cgb.ki.se) and TFSearch (http://www.cbrc.jp/research/db/ TFsearch.html) at a default threshold score of 85.0.
LXR-a gene silencing through siRNA construct LXR-a siRNA and scrambled siRNA (control) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were transfected into human keratinocytes maintained in an in vitro culture using transfection reagent (Santa Cruz Biotechnology Inc.). 22-R hydroxy cholesterol (Sigma-Aldrich), a natural agonist of the LXR-a protein, was added after 24 h to one of the LXR-a-specific siRNA-treated wells at a concentration of 20 mM. Furthermore, to access the efficiency of siRNA transfection, flouroscein-A-conjugated (Santa Cruz Biotechnology Inc.) control-scrambled sequence was used. Efficiency was found to be B70-80%.
Expression of LXR-a transcriptome
(a) The transcriptional expression of LXR-a, as well as its effecter genes PPAR-g, VDR, CAT, IL-6, IL-8 and IFN-g (primer sequences given in Table 1 ), was studied in the RNA extracted from LXR-a-specific siRNAtreated keratinocytes, LXR-a-specific siRNA-treated þ 22R hydroxycholestrol (after 24 h)-treated keratinocytes incubated for 48 h and from the cultured keratinocytes derived from the lesional site and symptomless skin of psoriatic patients and clinically healthy subjects using standard protocol. 30 Genespecific primers and the standard reverse transcrip- tase-PCR method were used to amplify gene products. Invariant control gene expression was used as a control for RNA loading and reverse transcription efficiency. PCR reaction products were resolved on 2% ethidium bromide-stained agarose gels, followed by densitometric scanning of each band on the gel. The intensity ratio of target mRNA (having amplification pattern of log phase) to invariant control gene mRNA for each gene was expressed as a percentage of that in control siRNAtransfected cells and cultured keratinocytes derived from the lesional site and symptomless skin of psoriatic patients and clinically healthy subjects. (b) Real-time reverse transcriptase-PCR was carried out for the LXR-a gene using Brilliant II Syber GREEN QPCR master mix (Stratagene, La Jolla, CA, USA) involving a difference in C T values (threshold cycle). b-actin was used as an internal control.
Translational expression of LXR-a Proteins were extracted from both siRNA-transfected cultured keratinocytes and cultured keratinocytes derived from the lesional site and symptomless skin of psoriatic patients and clinically healthy subjects. Equal amounts of proteins per sample were electrophoresed in polyacrylamide gels using the SDS-discontinuous buffer system described by Laemmli. 31 The resolved proteins were then electroblotted onto a nitrocellulose membrane using standard protocol. 32 These blots were developed using an antibody against b-actin (Santa Cruz Biotechnology, raised in mouse), and LXR-a (Santa Cruz Biotechnology, raised in mouse) and horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). The relative levels of protein expression were determined by normalizing their individual band intensity to b-actin band intensity.
Flow cytometry
To evaluate the relationship between LXR-a gene expression and keratinocyte proliferation, the cell cycle of keratinocytes was analyzed by flow cytometry. For this, cells were permeabilized in 100% cold methanol for 10 min and then permeabilized cells were incubated with 15 ml propidium iodide (1 mg ml -1 ) for 30 min in the dark. The cells were then washed with ice-cold PBS and subjected to BD FACSCalibur (BD Biosciences, San Jose, CA, USA).
Cell proliferation assay
For in vitro studies, the control siRNA-treated and LXRa-specific siRNA-treated keratinocytes were labeled with 5-bromodeoxyuridine using the in situ cell proliferation FLUOS (Roche, Nutley, NJ, USA) kit, according to the manufacturer's protocol.
Catalase enzyme activity
Keratinocytes derived from the normal and lesional skin of psoriatic patients were cultured till confluency. The cells were then lysed using 100 ml of lysis buffer in each well. The lysate was centrifuged to settle the debris and the supernatant was collected. Supernatant of 50 ml was retained for protein estimation and the rest of the lysate was used for the estimation of catalase activity using the standard protocol. 33 
Statistical methods
Polymerase chain reaction results were expressed as the percentage fold increase/decrease over the given control values for each set of experiments. Data were presented as mean±s.d. of six independent experiments for each type of study. Western blot results were also expressed as the percentage fold decrease over the given controls for each set of experiments. Data were compared using Student's t-test (SPSS 11.5, http://en.softonic.com/s/ spss11.5). Probability values of o0.05 and 0.001 were considered to be significant. Abbreviations: IL-6, interleukin-6; IL-8, interleukin-8; IFN-g, interferon-gamma; LXR-a, liver X receptor-alpha; PPAR-g, peroxisome proliferator-activated receptor-gamma; VDR, vitamin D receptor.
